Our data reveals the oncogenic effect of an Ikaros/MYCBP2/c-MYC axis in adult ALL, and suggests a mechanism by which CK2 inhibitors exert their anti-leukemia effect. The gene discussed is MYCBP2; the disease is acute lymphoblastic leukemia.